Company intelligence / Profile preview

Heronova

Cary, North Carolina, United Statesid.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

Heron Therapeutics has several FDA-approved products on the market for acute care and oncology supportive care. These include CINVANTI for chemotherapy-induced nausea/vomiting, ZYNRELEF for postoperative pain management, APONVIE for postoperative nausea/vomiting, and Sustol for extended-release antiemetic therapy. The company reported $144 million in net revenue in 2024 with positive net income in Q4 2024. Recent clinical progress includes expanded indications for ZYNRELEF.

Therapeutic areas: GastroenterologyNeurologyOncology
Modalities: Small moleculePolymer-based drug deliveryExtended-release injectable formulations
Industry: Biotech

Partnerships

Crosslink relationship to expand promotional reach of ZYNRELEF

Beyond the preview

Go deeper on Heronova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heronova.

Explore the full profile